Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931337 | 1.00 | PIK3CA (0.32) | PIK3CAPIK3C3CYP17A1 | |
| SCHEMBL931333 | 1.00 | PIK3CA (0.32) | PIK3CAPIK3C3CYP17A1 | |
| SCHEMBL930654 | 0.83 | PIK3CA (0.33) | PIK3CAPIK3C3 | |
| SCHEMBL930652 | 0.83 | PIK3CA (0.33) | PIK3CAPIK3C3 | |
| SCHEMBL930655 | 0.83 | PIK3CA (0.33) | PIK3CAPIK3C3 | |
| SCHEMBL22110830 | 0.78 | — | — | |
| SCHEMBL931314 | 0.77 | PIK3CA (0.53) | PIK3CAPIK3C3 | |
| SCHEMBL931315 | 0.77 | PIK3CA (0.53) | PIK3CAPIK3C3 | |
| SCHEMBL931317 | 0.77 | PIK3CA (0.53) | PIK3CAPIK3C3 | |
| SCHEMBL4416230 | 0.77 | LATS1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| CN-104603113-B | Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one and 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives comprising substituted morpholines, preparation thereof and pharmaceutical use thereof | 赛诺菲 | 2020-01-21 | — | — | CN | disclosed |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2019-09-26 | — | — | US | disclosed |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2019-09-26 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| EP-2655375-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| WO-2012085244-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | WO | disclosed |
| EP-2448940-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | MTX1, RDX, MTX2 | PIK3CA 3685/4885PIK3C3 2704/4885CYP17A1 1827/4885 |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | CBR3, MTX1, CBR1 | PIK3CA 3644/4885PIK3C3 2701/4885CYP17A1 2228/4885 |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | DPYD, TYMP, DHPS | PIK3CA 192/4885PIK3C3 1318/4885CYP17A1 751/4885 |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | ALK, HAX1, HCLS1 | PIK3CA 3059/4885PIK3C3 3977/4885CYP17A1 3091/4885 |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | CCNY, CBR3, CBR1 | PIK3CA 3887/4885PIK3C3 2808/4885CYP17A1 2311/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | PIK3CA 385/4885PIK3C3 4727/4885CYP17A1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.